Five FDA-approved therapies across four mechanisms now compete in a market that had none in 2021 — and 30–40% of patients still progress to kidney failure without disease modification.
Until December 2021, no therapy was approved specifically for IgA nephropathy; management rested on renin-angiotensin system (RAS) blockade and blood-pressure control. By mid-2026 the FDA had approved five disease-specific agents across four mechanisms: targeted-release budesonide (Tarpeyo, Calliditas/Otsuka), the dual endothelin-A/angiotensin receptor antagonist sparsentan (Filspari, Travere), the selective endothelin-A antagonist atrasentan (Vanrafia, Novartis), the oral factor B / alternative-complement inhibitor iptacopan (Fabhalta, Novartis), and the first-in-class anti-APRIL monoclonal antibody sibeprenlimab (Voyxact, Otsuka). Four are oral; sibeprenlimab is a self-administered subcutaneous injection.
Every agent won accelerated approval on reduction of proteinuria (the surrogate the FDA accepts as reasonably likely to predict benefit), and targeted-release budesonide and sparsentan have since added eGFR-slope confirmation. The commercial contest is now between mechanisms: does a prescriber layer an endothelin antagonist, a complement inhibitor or an APRIL inhibitor onto optimized supportive care (RAS blockade plus an SGLT2 inhibitor)? IgA nephropathy still carries a 30–40% lifetime risk of progression to end-stage kidney disease, and the RaDaR registry reports median kidney survival of roughly 11 years from diagnosis — the clinical urgency that underwrites the launch wave.
FDA-approved IgA nephropathy therapies — United States, 2026
| Drug (Brand / INN) | Mechanism | Company | US Approval | Key Trial Result | Route / Access |
|---|---|---|---|---|---|
| Filspari (sparsentan) | Dual endothelin-A + angiotensin receptor antagonist | Travere | Accelerated Feb 2023; full Sep 2024 | PROTECT: UPCR −49.8% vs −15.1% irbesartan at 36 wk; eGFR-slope benefit at 2 yr | Oral; REMS (hepatotoxicity); Part D |
| Tarpeyo (budesonide, targeted-release) | Gut-directed corticosteroid; lowers Gd-IgA1 | Calliditas / Otsuka | Accelerated Dec 2021; full Dec 2023 | NefIgArd: 2-yr eGFR benefit +5.05 mL/min/1.73m² vs placebo | Oral 9-month course; Part D |
| Fabhalta (iptacopan) | Oral factor B / alternative-complement inhibitor | Novartis | Accelerated Aug 2024 | APPLAUSE-IgAN: UPCR 38.3% lower vs placebo at 9 mo | Oral; Part D |
| Vanrafia (atrasentan) | Selective endothelin-A antagonist | Novartis | Accelerated Apr 2025 | ALIGN: UPCR −38.1% vs −3.1% placebo at 36 wk | Oral; no REMS; Part D |
| Voyxact (sibeprenlimab) | Anti-APRIL monoclonal antibody (first-in-class) | Otsuka | Accelerated Nov 2025 | VISIONARY: UPCR 51.2% lower vs placebo at 9 mo | SC self-administered q4w; Part D |
Sources: FDA Drugs@FDA (approval status and dates); PROTECT, Lancet 2023 (PMID 37015244; 37931634); NefIgArd, Lancet 2023 (PMID 37591292); APPLAUSE-IgAN, NEJM 2024 (PMID 39453772); ALIGN, NEJM 2024 (PMID 39460694); VISIONARY, NEJM 2025 (PMID 41211929). Sibeprenlimab approval per Otsuka; openFDA listing pending.
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- • Proteinuria reduction across PROTECT, NefIgArd, APPLAUSE-IgAN, ALIGN and VISIONARY • eGFR-slope evidence: which agents have confirmatory kidney-function data vs proteinuria-only accelerated approval • Oral vs subcutaneous administration and dosing cadence by product • Mechanistic positioning: where each class fits on optimized supportive care (RAS blockade + SGLT2i)
Delivers
- • Representative commercial and Part D prior-authorization criteria by product • Proteinuria and eGFR entry thresholds and required duration of optimized RAS blockade ± SGLT2i • Pharmacy-benefit (Part D) routing for all five patient-administered agents • Filspari REMS hepatotoxicity monitoring and its access friction vs REMS-free competitors
Delivers
- • Phase 3 anti-APRIL and BAFF/APRIL agents: zigakibart (Novartis), atacicept (Vera), telitacicept (RemeGen) — mechanism, trial ID, expected readout • Terminal complement (ravulizumab) Phase 3 status • ICER 2026 IgAN assessment: cost-effectiveness estimates and the CTAF review timeline • eGFR confirmatory readouts that could convert accelerated approvals and reset payer posture
Custom brief delivered in 72 hours.
Commission This BriefWhat's inside
- Before December 2021, no therapy was approved specifically for IgA nephropathy; management relied solely on RAS blockade.
- Why five FDA-approved agents across four mechanisms now exist, up from zero disease-specific therapies just five years ago.
- PROTECT trial data show sparsentan reducing proteinuria by 49.8% versus 15.1% for irbesartan at 36 weeks.
- Why sibeprenlimab, the first-in-class anti-APRIL antibody, cut proteinuria 51.2% versus placebo in the VISIONARY trial.
- Why every approved IgAN agent won accelerated approval on proteinuria reduction, the FDA's accepted surrogate endpoint.
- Only budesonide and sparsentan have since added confirmatory eGFR-slope data, with Tarpeyo showing a 5.05 mL/min/1.73m2 benefit.
- Why Filspari's REMS hepatotoxicity monitoring requirement creates access friction versus its REMS-free competitor atrasentan.
- All five IgAN agents route through Medicare Part D, from four oral products to sibeprenlimab's subcutaneous every-4-week injection.
- The KDIGO 2025 IgAN/IgAV guideline update now governs how prescribers sequence the five new mechanisms.
- A 30-40% lifetime risk of end-stage kidney disease and an 11-year median kidney survival underpin the urgency behind treatment sequencing.
- Phase 3 pipeline agents zigakibart, atacicept, and telitacicept target the same APRIL/BAFF pathway as sibeprenlimab.
- Why the ICER 2026 IgA nephropathy review's cost-effectiveness verdict could reset payer posture across all five approved agents.
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx brief is built from primary regulatory sources (FDA Drugs@FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer policy documentation — not secondary summaries, market-research reports, or unverified estimates. Findings are independently verified before inclusion; if a figure cannot be sourced to a live record, it does not ship.
US IgA nephropathy Competitive Intelligence sources: FDA Drugs@FDA (approval status and dates), primary trial publications in the Lancet and the New England Journal of Medicine (PROTECT, NefIgArd, APPLAUSE-IgAN, ALIGN, VISIONARY), ClinicalTrials.gov pipeline registrations, the KDIGO 2025 IgAN/IgAV guideline, the ICER 2026 IgA nephropathy assessment, and US epidemiology from the American Journal of Nephrology and the RaDaR registry (CJASN).
- PROTECT sparsentan results verified against Lancet primary publications (PMID 37015244 interim; PMID 37931634 two-year)
- NefIgArd, APPLAUSE-IgAN, ALIGN and VISIONARY results verified against primary publications (PMID 37591292; 39453772; 39460694; 41211929)
- US incidence and racial variation verified against the American Journal of Nephrology diverse-population study (PMID 39496243)
- Long-term progression benchmark verified against the RaDaR registry, CJASN (PMID 37055195)
Frequently asked questions
Commission this brief
AXLRx delivers US IgA nephropathy competitive intelligence built for pharma and biotech commercial, access, and medical affairs teams. Custom brief in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified brief in 72 hours with optional analyst readout.